GSA Capital Partners’s Akebia Therapeutics AKBA Stock Holding History

GSA Capital Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97K	Buy	+85,049	New	+$101K	0.01%	1624
2025 Q4	–	Sell	-182,443	Closed	-$498K	–	1633
2025 Q3	$498K	Buy	+182,443	New	+$607K	0.04%	849
2022 Q4	–	Sell	-486,568	Closed	-$154K	–	1421
2022 Q3	$154K	Buy	+486,568	New	+$191K	0.02%	1288
2022 Q2	–	Sell	-54,370	Closed	-$39K	–	1359
2022 Q1	$39K	Buy	+54,370	New	+$116K	0.01%	1345
2021 Q4	–	Sell	-254,376	Closed	-$733K	–	1382
2021 Q3	$733K	Buy	+254,376	New	+$726K	0.07%	461
2021 Q1	–	Sell	-128,626	Closed	-$360K	–	1066
2020 Q4	$360K	Buy	128,626 +38,963	+43%	+$114K	0.06%	637
2020 Q3	$225K	Buy	+89,663	New	+$787K	0.04%	931
2019 Q4	–	Sell	-26,187	Closed	-$103K	–	1407
2019 Q3	$103K	Buy	+26,187	New	+$112K	0.01%	1277
2016 Q2	–	Sell	-10,881	Closed	-$98K	–	1714
2016 Q1	$98K	Buy	+10,881	New	+$88.2K	0.01%	1584

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GSA Capital Partners's AKBA Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 85,049 shares worth $97K. The stake represents 0.01% of the portfolio and ranks #1624 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in AKBA as recently as Q3 2025.

GSA Capital Partners first reported a position in AKBA in Q1 2016 and has held it in 9 quarters since. The position peaked at $733K in Q3 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

GSA Capital Partners held 85,049 shares of Akebia Therapeutics worth $97K as of Q2 2026.
Akebia Therapeutics was a new GSA Capital Partners position in Q2 2026.
Akebia Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1624 holding.
GSA Capital Partners first reported a position in Akebia Therapeutics in Q1 2016 and has held it in 9 quarters since.
GSA Capital Partners's Akebia Therapeutics position peaked at $733K in Q3 2021.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.